Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* COUCHMAN JONATHAN	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS, INC. [ ENZN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 600 FIFTH AVENUE, 2ND FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 8/24/2020
(Street) NEW YORK, NY 10020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.01 par value ⁽¹⁾								4717666	I	By Jonathan Couchman ⁽²⁾
Common Stock, $0.01 par value ⁽¹⁾								400000	I	By Couchman Family Fund ⁽³⁾
Common Stock, $0.01 par value ⁽¹⁾								2100524	I	By Xstelos Corp. ⁽⁴⁾
Common Stock, $0.01 par value ⁽¹⁾								633264	I	By Myrexis, Inc. ⁽⁵⁾
Common Stock, $0.01 par value ⁽¹⁾	8/24/2020		S		52100	D	$0.1834	1615194	I	By Harper Asset Management LLC ⁽⁶⁾
Common Stock, $0.01 par value ⁽¹⁾	8/25/2020		S		25000	D	$0.1913	1590194	I	By Harper Asset Management LLC ⁽⁶⁾
Common Stock, $0.01 par value ⁽¹⁾								0	I	By Michael Pearce ⁽⁷⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis"), Brian Harper, Harper Asset Management, LLC ("HAM"), and Michael Pearce, (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
(2)	Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.
(3)	Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
(4)	Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
(5)	Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
(6)	Represents shares owned directly by HAM. Mr. Harper is the President of HAM. By virtue of this relationship, Mr. Harper may be deemed to beneficially own the Shares owned directly by HAM. Mr. Harper expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
(7)	Represents shares owned directly by Michael Pearce. Mr. Pearce expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
COUCHMAN JONATHAN 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020		X
Couchman Family Fund 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020		X
Xstelos Corp. 1105 NORTH MARKET STREET SUITE 1300 WILMINGTON, DE 19801		X
Myrexis, Inc. 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020		X
Harper Brian James 2248 MARINER DR. LONGMONT, CO 80503				See explanation of responses
HARPER ASSET MANAGEMENT LLC 2248 MARINER DR. LONGMONT, CO 80503				See explanation of responses
Pearce Michael Cooper 193 AUDUBON TRAIL CASHIERS, NC 28717				See explanation of responses

Signatures
/s/ Jonathan Couchman		8/26/2020
^**Signature of Reporting Person		Date
Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee		8/26/2020
^**Signature of Reporting Person		Date
Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer		8/26/2020
^**Signature of Reporting Person		Date
Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer		8/26/2020
^**Signature of Reporting Person		Date
/s/ Jonathan Couchman, attorney-in-fact for Brian Harper		8/26/2020
^**Signature of Reporting Person		Date
Harper Asset Management, LLC; By: /s/ Brian Harper		8/26/2020
^**Signature of Reporting Person		Date
/s/ Jonathan Couchman, attorney-in-fact for Michael Pearce		8/26/2020
^**Signature of Reporting Person		Date